Back to Authors

Bahlis, Nizar Jacques

0000-0001-7353-7034

A5065238694 | I168635309

Mayo Clinic

University of Calgary

Citations 86

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

HemaSphere | May 10, 2023 | Volume: 7 | Issue: S2 | Pages: 7-8

10.1097/01.hs9.0000936124.56965.24

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

New England Journal of Medicine | February 10, 2023 | Volume: 388 | Issue: 11 | Pages: 1002-1014

10.1056/nejmoa2213614 | PMID 36762851

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4415-4417

10.1182/blood-2022-157547

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7297-7300

10.1182/blood-2022-163494

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10133-10136

10.1182/blood-2022-163555

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145

10.1182/blood-2022-165524

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10150-10153

10.1182/blood-2022-163335

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12997-12997

10.1182/blood-2022-169920

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4242-4244

10.1182/blood-2022-160195

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 826-827

10.1097/01.hs9.0000846612.13339.9e